These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20961435)

  • 1. The 6th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis: A half-time review of lymphatic filariasis elimination and its integration with the control of other neglected tropical diseases.
    Addiss D;
    Parasit Vectors; 2010 Oct; 3():100. PubMed ID: 20961435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of lymphatic filariasis as a public health problem in Malawi.
    Chiphwanya J; Mkwanda S; Kabuluzi S; Mzilahowa T; Ngwira B; Matipula DE; Chaponda L; Ndhlova P; Katchika P; Mahebere Chirambo C; Moses P; Kumala J; Chiumia M; Barrett C; Betts H; Fahy J; Rebollo Polo M; Reimer L; Stanton MC; Thomas B; Freer S; Molyneux DH; Bockarie MJ; Mackenzie CD; Taylor MJ; Martindale S; Kelly-Hope LA
    PLoS Negl Trop Dis; 2024 Feb; 18(2):e0011957. PubMed ID: 38363794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis.
    Kastner RJ; Sicuri E; Stone CM; Matwale G; Onapa A; Tediosi F
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005934. PubMed ID: 28949987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. African regional progress and status of the programme to eliminate lymphatic filariasis: 2000-2020.
    Deribe K; Bakajika DK; Zoure HM; Gyapong JO; Molyneux DH; Rebollo MP
    Int Health; 2020 Dec; 13(Suppl 1):S22-S27. PubMed ID: 33349875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of lymphatic filariasis: current perspectives on mass drug administration.
    Gyapong JO; Owusu IO; da-Costa Vroom FB; Mensah EO; Gyapong M
    Res Rep Trop Med; 2018; 9():25-33. PubMed ID: 30050352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic filariasis in Fiji: progress towards elimination, 1997-2007.
    Manolas RK; Kama M; Rainima-Qaniuci M; Bechu VD; Tuibeqa S; Winston MV; Ram N; Naqio F; Ichimori K; Capuano C; Ozaki M; Kim SH; Aratchige P; Sahukhan A; Graves PM
    Trop Med Health; 2020; 48():88. PubMed ID: 33132735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt.
    Ramzy RMR; Kamal HA; Hassan MA; Haggag AA
    Acta Trop; 2019 Nov; 199():105121. PubMed ID: 31400299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significant scale up and success of Transmission Assessment Surveys 'TAS' for endgame surveillance of lymphatic filariasis in Bangladesh: One step closer to the elimination goal of 2020.
    Shamsuzzaman AK; Haq R; Karim MJ; Azad MB; Mahmood AS; Khair A; Rahman MM; Hafiz I; Ramaiah KD; Mackenzie CD; Mableson HE; Kelly-Hope LA
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005340. PubMed ID: 28141812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa.
    Silumbwe A; Zulu JM; Halwindi H; Jacobs C; Zgambo J; Dambe R; Chola M; Chongwe G; Michelo C
    BMC Public Health; 2017 May; 17(1):484. PubMed ID: 28532397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The story of Lymphatic Filariasis elimination as a public health problem from Yemen.
    Al-Kubati AS; Al-Samie AR; Al-Kubati S; Ramzy RMR
    Acta Trop; 2020 Dec; 212():105676. PubMed ID: 32828916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphatic Filariasis (Elephantiasis) Elimination: A public health success and development opportunity.
    Molyneux D
    Filaria J; 2003 Sep; 2(1):13. PubMed ID: 13129436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex emergencies and the control and elimination of neglected tropical diseases in Africa: developing a practical approach for implementing safe and effective mapping and intervention strategies.
    Kelly-Hope LA; Sanders AM; Harding-Esch E; Willems J; Ahmed F; Vincer F; Hill R
    Confl Health; 2021 Mar; 15(1):18. PubMed ID: 33789715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roadmap towards elimination of lymphatic filariasis by 2030: insights from quantitative and mathematical modelling.
    NTD Modelling Consortium Lymphatic Filariasis Group
    Gates Open Res; 2019; 3():1538. PubMed ID: 31728440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.
    Stone CM; Kastner R; Steinmann P; Chitnis N; Tanner M; Tediosi F
    BMJ Glob Health; 2016; 1(1):e000021. PubMed ID: 28588916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical approach for scaling up the alternative strategy for the elimination of lymphatic filariasis in
    Kelly-Hope LA; Stanton MC; Zouré HGM; Kinvi BE; Mikhailov A; Tekle A; King JD
    Glob Health Res Policy; 2017; 2():12. PubMed ID: 29202080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community-based field implementation scenarios of a short message service reporting tool for lymphatic filariasis case estimates in Africa and Asia.
    Mableson HE; Martindale S; Stanton MC; Mackenzie C; Kelly-Hope LA
    Mhealth; 2017; 3():28. PubMed ID: 28828375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress towards elimination of lymphatic filariasis in the Eastern Mediterranean Region.
    Ramzy RMR; Al Kubati AS
    Int Health; 2020 Dec; 13(Suppl 1):S28-S32. PubMed ID: 33349874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of lymphatic filariasis: do we have the drugs to complete the job?
    Bockarie MJ; Deb RM
    Curr Opin Infect Dis; 2010 Dec; 23(6):617-20. PubMed ID: 20847694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs.
    Kastner RJ; Stone CM; Steinmann P; Tanner M; Tediosi F
    PLoS Negl Trop Dis; 2015; 9(10):e0004147. PubMed ID: 26451729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis.
    Michael E; Singh BK
    BMC Med; 2016 Jan; 14():14. PubMed ID: 26822124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.